Figure 5
In vivo efficacy of anti–CD79b-vcMMAE compared with standard of care. Mouse xenograft models of NHL with a starting tumor volume of approximately 200 mm3 treated with a single dose of anti–CD79b-vcMMAE compared with a single treatment of rituximab, CHOP, and rituximab + CHOP. (A) Ramos RA1 xenografts with 9 mice per group treated with 5 mg ADC/kg mouse of anti–CD79b-vcMMAE as indicated. (B) Granta xenografts with 9 mice per group treated with 5 mg ADC/kg mouse of anti–CD79b-vcMMAE as indicated. (C) WSU-DLCL2 xenografts with 10 mice per group treated with 7 mg ADC/kg mouse of anti–CD79b-vcMMAE as indicated.
